Note

This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

• The use of interpreter services where necessary,
• Advising consumers of their choice and ensuring informed consent is obtained,
• Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
• Documenting all care in accordance with mandatory and local requirements

Synonyms

Phytomenadione, vitamin K₁, phytonadione
Dose and Indications

**Prophylaxis against Vitamin K Deficiency Bleeding**

Intramuscular dosing is the preferred approach. The alternative oral regime should only be offered where parents refuse the intramuscular dose.

**Intramuscular (preferred method)**

For neonates ≤1500 grams give 0.5 mg as single dose at birth

For neonates >1500 grams give 1 mg as single dose at birth

**Oral**

Oral therapy is given in up to three separate 2 mg doses at:

- Birth;
- 3 to 5 days of age; and
- The fourth week of life (breastfed babies only)

This regimen has the potential for poor compliance. If using this method, the initiating prescriber must ensure that ALL doses are prescribed.

**Treatment of Vitamin K Deficiency Bleeding**

**Intravenous, Intramuscular**

Administer 1 to 2 mg repeated every 4 hours when required

Administration of fresh frozen plasma to replace clotting factors will be necessary in the presence of active bleeding

**Cholestasis**

**Intramuscular**

Administer 1 mg once a fortnight increasing dose as required at Neonatal Consultant discretion.
Preparation and Administration

### Intramuscular

<table>
<thead>
<tr>
<th>Dose</th>
<th>0.5mg</th>
<th>1mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.05mL</td>
<td>0.1mL</td>
</tr>
</tbody>
</table>

Use anterolateral thigh for IM administration.

Discard remaining solution.

### Intravenous

<table>
<thead>
<tr>
<th>Dose</th>
<th>0.5mg</th>
<th>1mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.05mL</td>
<td>0.1mL</td>
</tr>
</tbody>
</table>

Administer with a push over at least 30 seconds.

### Oral

The injection can be used for oral administration. Each 0.2mL contains 2mg of vitamin K.

If there are any concerns that any of the oral doses are not retained (through vomiting or regurgitation within 1 hour of administration), then repeat the dose.

### Compatible Fluids

- Glucose 5%
- Sodium chloride 0.9%

### Adverse Effects

#### Common

Pain, tenderness and erythema at injection site (intramuscular administration).

#### Infrequent

Hypersensitivity-like reactions with rapid intravenous administration

#### Rare

Hyperbilirubinaemia through displacement of bilirubin (especially in preterm infants)

### Monitoring

- Check prothrombin time when treating clotting abnormalities (a minimum of 4 hours post therapy is needed for measurable improvement)
Practice Points

- An extensive review of the medical literature has concluded that there is no association between vitamin K and childhood cancer, regardless of the route of administration. Link to parent information brochure: [http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/ch38_vitamin_k_brochure_2010.pdf](http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/ch38_vitamin_k_brochure_2010.pdf)

- Oral prophylaxis is contraindicated in infants who are premature, unstable, on antibiotics, have cholestasis, or have diarrhoea

- Parents should receive written information during the antenatal period about the importance of vitamin K prophylaxis, and the options and relevance of oral or intramuscular prophylaxis

- A mechanism should be in place to ensure that the decision made antenatally about the method of prophylaxis is still valid and is communicated to staff caring for the mother during childbirth and postnatally. Health practitioners and institutions should ensure that appropriate informed consent procedures are in place and are followed

- Neonates experiencing birth asphyxia or bleeding problems, those born to mothers with liver disease or taking enzyme inducing anticonvulsant drugs (carbamazepine, phenobarbital, phenytoin), rifampicin or warfarin are at higher risk of vitamin K deficiency bleeding

- Neonates with cholestatic disease must be given vitamin K either intramuscularly or intravenously because oral absorption is likely to be impaired

- Vitamin K degrades in only a few hours of exposure to light. Do not leave out on bench exposed to sunlight in preparation for a newborn to arrive in the Unit.

References


Version control and change history PDS reference: CG064

<table>
<thead>
<tr>
<th>Version</th>
<th>Date from</th>
<th>Date to</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>November 2012</td>
<td>current</td>
<td>Original version</td>
</tr>
</tbody>
</table>